EPISODE · Aug 7, 2026 · 38 MIN
New and Emerging Targeted Therapies for Patients With DLBCL
from Decera Clinical Education Oncology Podcast · host Gilles Salles MD PhD, Pier Luigi Zinzani MD PhD
In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice Key Ongoing Trials of new and novel agents in DLBCL Key Presentations/Results at EHA 2026 in DLBCL Presenters: Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program:https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
The management of patients with DLBCL is rapidly changing with several targeted agents across different drug classes on the near horizon. Experts discuss the potential utility of surovatamig, a novel bispecific antibody targeting CD19 and CD3 in overcoming resistance to CD20-targeted therapies, and the potential roles of golcadomide, a first-in-class oral CELMoD, and tafasitamab plus lenalidomide and R-CHOP in untreated DLBCL. They also discuss ongoing trials of other bispecific antibodies and acalabrutinib, a BTK inhibitor, in DLBCL. Listen to this podcast with 2 experts from Europe and the United States discussing the unmet clinical needs in DLBCL, the expanding role of approved targeted therapies, challenges with access to these new therapies in different regions, important ongoing clinical trials of new and novel agents in DLBCL that are poised to change practice, and key presentations and results in DLBCL reported at the recent 2026 European Hematology Association Congress in Sweden.
NOW PLAYING
New and Emerging Targeted Therapies for Patients With DLBCL
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.